靶向与非靶向肝活检具有相同的并发症风险
该研究分析了2010年1月至2015年12月间2137例患者共2405次超声引导下肝活检,比较靶向活检(用于局灶性肝病变定性)与非靶向活检(用于慢性肝病评估)的并发症发生率和危险因素。结果显示靶向活检明显症状发生率高于非靶向活检(7.4% vs 3.5%,p<0.001),但并发症发生率无显著差异(1.9% vs 1.2%,p=0.253);多因素分析中仅最大病灶直径与并发症发生独立相关(OR 1.014,p=0.018)。
要点
- 靶向与非靶向超声引导肝活检的并发症发生率无显著差异(1.9% vs 1.2%,p=0.253)。
- 靶向活检明显症状发生率高于非靶向活检(7.4% vs 3.5%,p<0.001),最常见为疼痛。
- 最大病灶直径是靶向活检并发症的独立危险因素(OR 1.014,p=0.018)。
核心结论
- 超声引导肝活检的不良事件发生率低,靶向与非靶向活检的并发症风险无差异;靶向活检中最大病灶直径而非强化模式是主要危险因素。
研究设计与样本
- 单中心回顾性分析,纳入2010年1月至2015年12月间2137例患者共2405次超声引导下肝活检,靶向活检用于局灶性肝病变定性,非靶向活检用于慢性肝病评估。
诊断标准与关键数值
- 明显症状定义为不良事件中的一类,并发症为另一类,需要栓塞或手术等特殊治疗者视为严重并发症。
- 靶向活检明显症状发生率7.4%(95/1283),非靶向活检3.5%(39/1122),p<0.001。
- 靶向活检并发症发生率1.9%(24/1283),非靶向活检1.2%(14/1122),p=0.253。
- 多因素分析中最大病灶直径与并发症发生独立相关(OR 1.014 [1.002-1.026],p=0.018)。
临床应用与阅片要点
- 靶向与非靶向肝活检的并发症风险相当,两者均可按常规进行术后监测。
- 病灶最大直径较大的靶向活检患者并发症风险略高,需更严密观察。
- 血清肌酐水平升高与并发症风险增加相关,应引起重视并加强活检后监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To reappraise the rate of and risk factors for complications of targeted and non-targeted US-guided liver biopsy in a large series.
METHODS: We analyzed 2405 liver biopsies performed in 2137 patients (58% males, mean age 54 ± 15 years old) between January 2010 and December 2015. Biopsies were performed for focal liver lesions characterization (targeted) or chronic liver disease assessment (non-targeted). Clinical, laboratory, and technical data were recorded. For targeted biopsies, we also recorded the largest diameter, location, enhancement pattern, and pathology. Advert events were divided into marked symptoms and complications. Those requiring specific treatment (embolization or surgery) were considered as severe.
RESULTS: A total of 1283 (53%) targeted and 1122 (47%) non-targeted biopsies were performed. Marked symptoms occurred after 134 biopsies (5.6%) (95 (7.4%) targeted and 39 (3.5%) non-targeted, p < 0.001), the most common being pain (109/134). Complications occurred after 38 biopsies (1.6%) (24 (1.9%) targeted and 14 (1.2%) non-targeted, p = 0.253) and were severe in 13 patients. In univariate analysis, prothrombin time (p = 0.006), serum creatinine level (p < 0.001), largest lesion diameter (p < 0.001), and tumor pathology (p = 0.040) were associated with the occurrence of complications but not platelet count or lesion enhancement pattern. In multivariate analysis, only the largest lesion diameter was retained (OR 1.014 [1.002-1.026], p = 0.018).
CONCLUSION: The rate of advert events after US-guided liver biopsy was low, with no difference between targeted and non-targeted biopsies. When focusing on targeted biopsies, the largest lesion diameter but not enhancement pattern appeared as the main risk factor.
KEY POINTS: • Targeted and non-targeted liver biopsies are associated with the same observed risk of complication. • Arterial phase hyperenhanced tumors on contrast-enhanced CT or MRI are not associated with a higher risk of complication when compared with non-hyperenhanced ones. • A high serum creatinine level is associated with a higher risk of complication and should motivate strict post-biopsy surveillance.
引用
- Maheux A, Purcell Y, Harguem S, et al. Targeted and non-targeted liver biopsies carry the same risk of complication. Eur Radiol. 2019. PMID: 31076864. doi:10.1007/s00330-019-06227-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。